Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Public ClinicalTrials.gov record NCT07590934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Study identification
- NCT ID
- NCT07590934
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Interventions
- AZD2265 (FPI-2265) Drug
- Palacaparib (AZD9574) Drug
- Docetaxel Drug
- AZD2287 (Imaging agent) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2026
- Primary completion
- Sep 24, 2029
- Completion
- Sep 24, 2029
- Last update posted
- Aug 26, 2026
2026 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Duarte | California | 91010 | Not yet recruiting |
| Research Site | Encino | California | 91436 | Not yet recruiting |
| Research Site | South Pasadena | California | 91030 | Recruiting |
| Research Site | Miami | Florida | 33165 | Recruiting |
| Research Site | Tampa | Florida | 33612 | Not yet recruiting |
| Research Site | Metairie | Louisiana | 70006 | Not yet recruiting |
| Research Site | Minneapolis | Minnesota | 55455 | Not yet recruiting |
| Research Site | Omaha | Nebraska | 68130 | Not yet recruiting |
| Research Site | New York | New York | 10065 | Not yet recruiting |
| Research Site | Portland | Oregon | 97239 | Not yet recruiting |
| Research Site | Houston | Texas | 77030 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07590934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07590934 live on ClinicalTrials.gov.